Biomarin (BMRN) analyst forecast and price target
Analyst forecast
Consensus of 31 analyst ratings
Based on 9 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $114.00 from $111.00 | Oct 14, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $60.00 | Sep 10, 2026 |
| Piper Sandler | Maintained | Overweight | $90.00 from $88.00 | Sep 1, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $60.00 from $59.00 | Aug 31, 2026 |
| Jefferies | Maintained | Buy | $105.00 from $104.00 | Aug 31, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $98.00 | Aug 19, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $59.00 from $60.00 | Aug 18, 2026 |
| Barclays | Maintained | Overweight | $111.00 from $105.00 | Aug 17, 2026 |
| Piper Sandler | Maintained | Overweight | $88.00 from $82.00 | Aug 17, 2026 |
| Canaccord Genuity | Maintained | Buy | $114.00 from $111.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $60.00 from $50.00 | Aug 7, 2026 |
| Oppenheimer | Maintained | Outperform | $97.00 from $95.00 | Aug 7, 2026 |
| Morgan Stanley | Maintained | Overweight | $124.00 from $119.00 | Aug 7, 2026 |
| Citigroup | Maintained | Buy | $76.00 from $75.00 | Jul 16, 2026 |
| RBC Capital | Maintained | Sector Perform | $62.00 from $66.00 | Jul 7, 2026 |
| Canaccord Genuity | Maintained | Buy | $111.00 from $116.00 | May 22, 2026 |
| Citigroup | Initiated Coverage | Buy | $75.00 | May 19, 2026 |
| B of A Securities | Maintained | Buy | $80.00 from $85.00 | May 19, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $50.00 from $55.00 | May 18, 2026 |
| Goldman Sachs | Maintained | Buy → Neutral | $69.00 | May 11, 2026 |
Frequently asked questions
What is the price target for BMRN stock?
The average 12-month analyst price target for Biomarin (BMRN) is $97.56, with a high estimate of $124.00 and a low of $60.00, across 9 analysts.
Is BMRN a buy, sell, or hold?
Analysts covering Biomarin currently average a Buy rating: 24 buy, 7 hold and 0 sell, from 31 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BMRN?
The average price target of $97.56 implies 72.10% upside from the last price of $56.69.
What is the latest analyst rating on BMRN?
On Oct 14, 2026, Barclays maintained Biomarin at Overweight with a price target of $114.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.